Identification of Distinct Molecular Subtypes of Endometrioid Adenocarcinoma
Endometrial carcinoma (EC) is one of the most common gynecological cancers worldwide. Endometrioid adenocarcinoma (EAC) is the major form of EC, accounting for 75–80% of cases. Currently, there is no molecular classification system for EAC, so there are no corresponding targeted treatments. In this...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-07-01
|
Series: | Frontiers in Genetics |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fgene.2021.568779/full |
id |
doaj-42d996f83cd04b0b930fde8fa463082b |
---|---|
record_format |
Article |
spelling |
doaj-42d996f83cd04b0b930fde8fa463082b2021-07-21T11:40:23ZengFrontiers Media S.A.Frontiers in Genetics1664-80212021-07-011210.3389/fgene.2021.568779568779Identification of Distinct Molecular Subtypes of Endometrioid AdenocarcinomaJia Lei0Shuping Yan1Xiangqian Guo2Fengling Wang3Guosen Zhang4Quancheng Kan5Ruixia Guo6Department of Gynecologic Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaDepartment of Gynecologic Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaJoint National Laboratory for Antibody Drug Engineering, Cell Signal Transduction Laboratory, Department of Preventive Medicine, School of Basic Medical Sciences, Institute of Biomedical Informatics, Henan University, Kaifeng, ChinaJoint National Laboratory for Antibody Drug Engineering, Cell Signal Transduction Laboratory, Department of Preventive Medicine, School of Basic Medical Sciences, Institute of Biomedical Informatics, Henan University, Kaifeng, ChinaJoint National Laboratory for Antibody Drug Engineering, Cell Signal Transduction Laboratory, Department of Preventive Medicine, School of Basic Medical Sciences, Institute of Biomedical Informatics, Henan University, Kaifeng, ChinaDepartment of Gynecologic Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaDepartment of Gynecologic Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaEndometrial carcinoma (EC) is one of the most common gynecological cancers worldwide. Endometrioid adenocarcinoma (EAC) is the major form of EC, accounting for 75–80% of cases. Currently, there is no molecular classification system for EAC, so there are no corresponding targeted treatments. In this study, we identified two distinct molecular subtypes of EAC with different gene expression patterns and clinicopathologic characteristics. Subtype I EAC cases, accounting for the majority of cases (56%), were associated with an earlier stage, a more well-differentiated grade, a lower tumor invasion rate, and a more favorable prognosis, and the median tumor necrosis percent (15%) was also significantly higher in subtype I EAC. In contrast, subtype II EAC represents high-grade EAC, with a higher tumor invasion rate and tumor weight. The up-regulated genes in subtype I EAC were associated with the immune response, defense response, cell motion, and cell motility pathway, whereas the up-regulated genes in subtype II EAC were associated with the cell cycle, DNA replication, and RNA processing pathways. Additionally, we identified three potential subtype-specific biomarkers, comprising MDM2 (MDM2 proto-oncogene) for subtype I, and MSH2 (mutS homolog 2) and MSH6 (mutS homolog 6) for subtype II.https://www.frontiersin.org/articles/10.3389/fgene.2021.568779/fullendometrioid adenocarcinomamolecular subtypemolecular signaturegene expression patternsubtype-specific treatment |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jia Lei Shuping Yan Xiangqian Guo Fengling Wang Guosen Zhang Quancheng Kan Ruixia Guo |
spellingShingle |
Jia Lei Shuping Yan Xiangqian Guo Fengling Wang Guosen Zhang Quancheng Kan Ruixia Guo Identification of Distinct Molecular Subtypes of Endometrioid Adenocarcinoma Frontiers in Genetics endometrioid adenocarcinoma molecular subtype molecular signature gene expression pattern subtype-specific treatment |
author_facet |
Jia Lei Shuping Yan Xiangqian Guo Fengling Wang Guosen Zhang Quancheng Kan Ruixia Guo |
author_sort |
Jia Lei |
title |
Identification of Distinct Molecular Subtypes of Endometrioid Adenocarcinoma |
title_short |
Identification of Distinct Molecular Subtypes of Endometrioid Adenocarcinoma |
title_full |
Identification of Distinct Molecular Subtypes of Endometrioid Adenocarcinoma |
title_fullStr |
Identification of Distinct Molecular Subtypes of Endometrioid Adenocarcinoma |
title_full_unstemmed |
Identification of Distinct Molecular Subtypes of Endometrioid Adenocarcinoma |
title_sort |
identification of distinct molecular subtypes of endometrioid adenocarcinoma |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Genetics |
issn |
1664-8021 |
publishDate |
2021-07-01 |
description |
Endometrial carcinoma (EC) is one of the most common gynecological cancers worldwide. Endometrioid adenocarcinoma (EAC) is the major form of EC, accounting for 75–80% of cases. Currently, there is no molecular classification system for EAC, so there are no corresponding targeted treatments. In this study, we identified two distinct molecular subtypes of EAC with different gene expression patterns and clinicopathologic characteristics. Subtype I EAC cases, accounting for the majority of cases (56%), were associated with an earlier stage, a more well-differentiated grade, a lower tumor invasion rate, and a more favorable prognosis, and the median tumor necrosis percent (15%) was also significantly higher in subtype I EAC. In contrast, subtype II EAC represents high-grade EAC, with a higher tumor invasion rate and tumor weight. The up-regulated genes in subtype I EAC were associated with the immune response, defense response, cell motion, and cell motility pathway, whereas the up-regulated genes in subtype II EAC were associated with the cell cycle, DNA replication, and RNA processing pathways. Additionally, we identified three potential subtype-specific biomarkers, comprising MDM2 (MDM2 proto-oncogene) for subtype I, and MSH2 (mutS homolog 2) and MSH6 (mutS homolog 6) for subtype II. |
topic |
endometrioid adenocarcinoma molecular subtype molecular signature gene expression pattern subtype-specific treatment |
url |
https://www.frontiersin.org/articles/10.3389/fgene.2021.568779/full |
work_keys_str_mv |
AT jialei identificationofdistinctmolecularsubtypesofendometrioidadenocarcinoma AT shupingyan identificationofdistinctmolecularsubtypesofendometrioidadenocarcinoma AT xiangqianguo identificationofdistinctmolecularsubtypesofendometrioidadenocarcinoma AT fenglingwang identificationofdistinctmolecularsubtypesofendometrioidadenocarcinoma AT guosenzhang identificationofdistinctmolecularsubtypesofendometrioidadenocarcinoma AT quanchengkan identificationofdistinctmolecularsubtypesofendometrioidadenocarcinoma AT ruixiaguo identificationofdistinctmolecularsubtypesofendometrioidadenocarcinoma |
_version_ |
1721292828687990784 |